Daiichi Sankyo Agrees to Pay $39 Million to Settle Benicar Kickback Allegations

Daiichi Sankyo Agrees to Pay $39 Million to Settle Benicar Kickback Allegations

Posted By Golomb & Honik || 24-Mar-2015

2015 did not start very well for pharmaceutical company Daiichi Sankyo. In January 2015, the company agreed to pay the United States and state Medicaid programs $39 million after allegations surfaced that they paid physicians kickbacks to prescribe drugs, such as Azor, Benicar, Tribenzor, and Welchol. This is in direct violation of the False Claims Act and the Anti-Kickback Statute. The Ant-Kickback Statute was enacted to ensure that a doctor’s best medical judgment was not influenced by payments or other gifts from pharmaceutical companies and medical device manufacturers.

The allegations were brought by the U.S. government and they stated that Daiichi Sankyo paid physicians improper kickbacks as part of speaker fees that ran from January 2005 through March 2011. “Schemes such as this are particularly abhorrent. Manufacturers and physicians who engage in them are cheating Medicare and Medicaid out of millions of dollars and threatening programs upon which many elderly and disabled Americans rely,” stated Inspector General Daniel R. Levinson.

Benicar Lawsuits

This is not the first time Daiichi Sankyo has been in trouble with the law. Because of the failure of the manufacturer to properly warn consumers about the potential risks of Benicar, lawsuits are being pursued. Former users of Benicar who suffered harm or injury from the drug are alleging symptoms of chronic diarrhea resulting in hospitalization, symptoms of sprue-like enteropathy, misdiagnosis of celiac disease, chronic malnutrition, dehydration, and abdominal pain. Sprue-like enteropathy is a serious medical condition that can have serious medical consequences for patients taking Benicar.

Allegations of designing a defective product, failure to warn, strict liability, negligence, unjust enrichment, breach of warranty, fraud and negligent misrepresentation are being claimed by many of the plaintiffs. Further, plaintiffs are claiming that the manufacturer of Benicar knew-or should have known-about the abdominal issues associated with the drug, yet failed to disclose those risks until the independent studies were released.

Other Issues Associated With Benicar

Benicar is manufactured by the Japanese drug company Daiichi Sankyo, Inc. in conjunction with Forest Laboratories. It is estimated that nearly two million patients received a prescription for Benicar in 2012; Benicar is currently the third-highest selling ARB blood pressure medication on the market. Some of the other potential dangers of Benicar include an irregular heartbeat, symptoms of arthritis, kidney disorders, skin rashes, chest and abdominal pain, chronic vomiting and liver disorders. Benicar currently contains only a black box warning for fetal toxicity, and pregnant women are warned against taking the drug. Benicar has not yet been recalled but the FDA did require the manufacturer to add a label warning which states Benicar could be associated with serious gastrointestinal side effects.

National Dangerous Drug Lawyers

If you have been diagnosed with sprue-like enteropathy or GI complications after using Benicar, your injuries may be the result of a drug manufacturer’s negligence. To learn more about your legal options or to schedule a free consultation call the Philadelphia class action lawyers at Golomb & Honik today at 1-800-355-3300 or 1-215-985-9177 or fill out our confidential Contact Form.

The national dangerous drug lawyers at Golomb & Honik have successfully represented individuals in Philadelphia, Pennsylvania, New Jersey, and throughout the United States.

Blog Home